The Pharma Data

MARCH 31, 2022

. €650 million fixed rate notes, due April 2029, bearing interest at an annual rate of 1.250%. million patients, provided with essential medicines by the global health unit, for the treatment of non-communicable diseases in 40 of the world’s poorest countries, between 2022 and 2026. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.

Treatment 52

Treatment Government Vaccine Disease 52

Vial

MARCH 1, 2024

billion by 2029. Existing lab services include bioanalytical, biomarker , and vaccine sciences labs in Virginia; a GMP lab in Ireland; central labs and biomarker operations in Belgium, Kentucky, and Singapore; and bioanalytical, biomarker, vaccine sciences, and central labs in China. from 2024 to reach US$129.8

Clinical Trials 52

Clinical Trials Clinical Research Trials Laboratories 52

Codon

FEBRUARY 23, 2025

million new HIV infections by 2029, undermining progress toward the UN’s goal. For that reason, long-term preventatives are probably a better strategy for controlling the disease. A lifelong HIV vaccine would be ideal, but developing one has proved difficult. By February, the U.S. Jerome Horwitz and Wolfram Ostertag.

Clinical Trials 68

Clinical Trials Virus Vaccine DNA 68